What Advantages Do Surveyed Oncologists and Payers Believe Emerging Therapies Must Offer to Gain Traction in This Market? The introduction of the HER2-targeting agent trastuzumab (Roche/Genentech/…
Idiopathic pulmonary fibrosis (IPF), although a rare disease, is one of the most common interstitial lung diseases (ILDs) and is characterized by irreversible loss of lung function leading to high…
A Survey of Noninterventional Cardiologists, Endocrinologists, and Managed Care Organization Pharmacy and Medical Directors The primary goal of therapy for individuals with dyslipidemia is to…
How Can Emerging Augmentation Strategies Be Differentiated to Maximize Uptake in a Mature and Genericized Market? Unipolar depression, which includes major depressive disorder (MDD), minor…
TreatmentTrends: Diabetic Retinopathy/Diabetic Macular Edema 2015 (US) is the fourth annual syndicated report series that offers a snapshot of DR and DME market dynamics and the competitive…
What Improvements Do Physicians and Payers Expect from Emerging Therapies? Owing to a lack of specific symptoms, the majority of patients with ovarian cancer (CaO) present at an advanced stage of…
What Attributes Will Distinguish Emerging Therapies, According to Physicians and Payers? Targeted therapies, particularly tyrosine kinase inhibitors (TKIs) that target angiogenesis, dominate the…
Can Targeting Patient Subpopulations Serve as a Market Access Lever? The asthma market is dominated by a number of effective and well-established treatments, including inhaled and oral therapies,…
As Anti-NGF Therapies Resume Phase III Trials, What Attributes of Emerging Therapies Will Most Influence Physician and Payer Decisions? Osteoarthritis (OA) is a tremendously prevalent condition,…
How Receptive Are Ophthalmologists and U.S. Payers to Emerging Therapies in This Underserved Market? Affecting more than 40 million people in its severe form, dry eye disease represents a large,…
Developing a biosimilar requires considerable investment and expertise. In order to maximize potential commercial return, biosimilar developers must adopt clear and effective strategies that…
Latest update: Global Biosimilars Pipeline updated on 31 July 2015 The biosimilars market is not all about the United States, Europe, and Japan. Although these developed markets account for 75% of…
Physician and Payer Expectations for Changes in Treatment Algorithms Monoclonal antibodies (MAbs) have become the standard of care in the treatment of non-Hodgkin’s lymphoma (NHL), colorectal…
The Alarming Scarcity of Treatment Options for These Pathogens Presents an Attractive Market Opportunity for Novel Antibiotics The carbapenems are a class of potent gram-negative antibiotics that…
This quarterly report series covers the management of dialysis and mid- to late-stage chronic kidney disease (CKD) patients from the perspective of nephrologists. Emphasis is on renal anemia…